Our Approach
Our proprietary, highly targeted antibody drug conjugates (ADCs) are armed with highly potent pyrrolobenzodiazepine (PBD)-based warheads to selectively kill cancer cells.
Pipeline
The selective targeting and unique mechanism of action of our ADCs enables the potential for our robust pipeline of therapies to have enhanced, durable efficacy and limited side effects in patients.
Clinical Trials
We are advancing our ADCs through clinical trials in multiple hematological and solid tumor indications, including a pivotal Phase II trial of ADCT-402 (loncastuximab tesirine) in patients with relapsed or refractory diffuse large B-cell lymphoma.
News
ADC Therapeutics Appoints Joseph Camardo, MD, as Head of Medical Affairs
10 January 2020
ADC Therapeutics Appoints Joseph Camardo, MD, as Head of Medical AffairsFormer Celgene and Wyeth leader with 30 years of global biopharmaceutical experience joins company as it prepares for first Biologics License Application (BLA) submission Lausanne, Switzerland, January 10, 2020 – ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent antibody drug conjugates (ADCs) for patients suffering from
ADC Therapeutics Announces Positive Results from Pivotal Phase 2 Clinical Trial of Single Agent Loncastuximab Tesirine (ADCT-402) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
9 January 2020
ADC Therapeutics Announces Positive Results from Pivotal Phase 2 Clinical Trial of Single Agent Loncastuximab Tesirine (ADCT-402) in Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaExceeded primary endpoint target with 45.5% overall response rate, including 20% complete response rate, in 145-patient trial On track for Biologics License Application (BLA) submission in 3Q 2020 Lausanne, Switzerland, January 9, 2020 – ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent antibody drug conjugates (ADCs)
ADC Therapeutics Announces Oral Presentation of Interim Efficacy Data from Pivotal Phase 2 Clinical Trial of ADCT-402 (Loncastuximab Tesirine) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma at 61st ASH Annual Meeting
9 December 2019
ADC Therapeutics Announces Oral Presentation of Interim Efficacy Data from Pivotal Phase 2 Clinical Trial of ADCT-402 (Loncastuximab Tesirine) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma at 61st ASH Annual MeetingData on 52 patients in the 145-patient clinical trial highlight ADCT-402 (loncastuximab tesirine) continues to demonstrate anti-tumor activity and manageable toxicity in heavily pretreated patients Biologics License Application submission planned for 2H 2020 Lausanne, Switzerland, December 9, 2019 – ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent antibody
